CD4+ T Cells and Cytokines in the Pathogenesis of Acquired Myasthenia Gravis

Although human and experimental acquired myasthenia gravis (MG) are prototypic antibody (Ab)‐mediated autoimmune diseases, synthesis of the pathogenic anti‐acetylcholine receptor (AChR) Abs, which are high affinity IgG, requires intervention of CD4+ T helper cells and their cytokines. Moreover, cytokine signaling is crucial for development, modulation, and downregulation of immune responses, and therefore influences the initiation and evolution of the anti‐AChR response in acquired MG. Cytokines are involved in the growth and differentiation of CD4+ T cells, and are secreted by activated CD4+ T cells as effectors of their functions: differentiated CD4+ T cells are classified into subtypes based on the cytokines they synthesize and secrete. Because cytokines are synthesized by and act on a variety of cells and because they may influence the synthesis and/or the activity of other cytokines, the effects of their signaling, in both normal and autoimmune responses, are complex and sometimes even contrasting, depending on the circumstances when the cytokine action took place. In this chapter, we will review studies on the effects on the development of acquired MG symptoms of several cytokines secreted by activated CD4+ T cells or influencing the activation of particular CD4+ T cell subsets.

[1]  Monica Milani,et al.  Myasthenia gravis: past, present, and future. , 2006, The Journal of clinical investigation.

[2]  H. Eng,et al.  Human monoclonal immunoglobulins that bind the human acetylcholine receptor , 1987, European journal of immunology.

[3]  J. Ihle The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[4]  H. Link,et al.  Mucosal tolerance: a two-edged sword to prevent and treat autoimmune diseases. , 1997, Clinical immunology and immunopathology.

[5]  A. O’Garra,et al.  Cytokines induce the development of functionally heterogeneous T helper cell subsets. , 1998, Immunity.

[6]  F. Shi,et al.  Natural killer cells determine the outcome of B cell–mediated autoimmunity , 2000, Nature Immunology.

[7]  Chuan-zhen Lu,et al.  Increase of circulating CD4+CD25+ T cells in myasthenia gravis patients with stability and thymectomy. , 2004, Clinical immunology.

[8]  R. Ruff,et al.  The Myasthenic Syndromes , 1996 .

[9]  A. Gurney,et al.  Interleukin-23 Promotes a Distinct CD4 T Cell Activation State Characterized by the Production of Interleukin-17* , 2003, The Journal of Biological Chemistry.

[10]  J. Banchereau,et al.  Interleukin-10 induces immunoglobulin G isotype switch recombination in human CD40-activated naive B lymphocytes , 1996, The Journal of experimental medicine.

[11]  Y. Ilan,et al.  Induction of immune tolerance: a role for Natural killer T lymphocytes? , 2005, Liver international : official journal of the International Association for the Study of the Liver.

[12]  J. Banchereau,et al.  Interleukin 10 induces B lymphocytes from IgA-deficient patients to secrete IgA. , 1994, The Journal of clinical investigation.

[13]  P. Berman,et al.  Linkage between the frequency of muscular weakness and loci that regulate immune responsiveness in murine experimental myasthenia gravis , 1980, The Journal of experimental medicine.

[14]  P. Karachunski,et al.  Absence of IFN-gamma or IL-12 has different effects on experimental myasthenia gravis in C57BL/6 mice. , 2000, Journal of immunology.

[15]  K. Bergström,et al.  Acetylcholine Receptor Antibody in Myasthenia Gravis: Purification and Characterization , 1978, Scandinavian journal of immunology.

[16]  J. Howard,et al.  CD4+ T cell response to the human acetylcholine receptor alpha subunit in myasthenia gravis. A study with synthetic peptides. , 1990, Journal of immunology.

[17]  K. Rajewsky,et al.  Generation and analysis of interleukin-4 deficient mice. , 1991, Science.

[18]  P. Christadoss Immunogenetics of experimental autoimmune myasthenia gravis. , 1989, Critical reviews in immunology.

[19]  L. Moiola,et al.  Myasthenia gravis. CD4+ T epitopes on the embryonic gamma subunit of human muscle acetylcholine receptor. , 1992, The Journal of clinical investigation.

[20]  V. Nussenzweig,et al.  Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids , 1987, The Journal of experimental medicine.

[21]  P. Christadoss,et al.  Tumor necrosis factor receptor p55 and p75 deficiency protects mice from developing experimental autoimmune myasthenia gravis , 2002, Journal of Neuroimmunology.

[22]  R. Locksley,et al.  Altered Immune Responses in Interleukin 10 Transgenic Mice , 1997, The Journal of experimental medicine.

[23]  L. Steinman,et al.  CD4+ T-cell subsets in autoimmunity. , 1997, Current opinion in immunology.

[24]  F. Shi,et al.  Tumor necrosis factor receptor-1 is critically involved in the development of experimental autoimmune myasthenia gravis. , 2000, International immunology.

[25]  H. Link,et al.  Mice with IFN-gamma receptor deficiency are less susceptible to experimental autoimmune myasthenia gravis. , 1999, Journal of immunology.

[26]  D Elmqvist Myasthenia Gravis , 1975, The Lancet.

[27]  N. Calcutt,et al.  Myasthenia gravis-like syndrome induced by expression of interferon gamma in the neuromuscular junction , 1995, The Journal of experimental medicine.

[28]  T. Mosmann,et al.  IL-10, a novel growth cofactor for mature and immature T cells. , 1990, Journal of immunology.

[29]  M. Shenoy,et al.  Major histocompatibility complex class II gene disruption prevents experimental autoimmune myasthenia gravis. , 1994, Journal of immunology.

[30]  M. Atassi,et al.  T lymphocyte recognition of acetylcholine receptor: Localization of the full T cell recognition profile on the extracellular part of the α chain of Torpedo californica acetylcholine receptor , 1987, European journal of immunology.

[31]  J. Lindstrom,et al.  Experimental autoimmune myasthenia: A model of myasthenia gravis in rats and guinea pigs , 1975, The Journal of experimental medicine.

[32]  P. Karachunski,et al.  Absence of IFN-γ or IL-12 Has Different Effects on Experimental Myasthenia Gravis in C57BL/6 Mice1 , 2000, The Journal of Immunology.

[33]  N. Sarvetnick,et al.  Loss of pancreatic islet tolerance induced by β-cell expression of interferon-γ , 1990, Nature.

[34]  P. Christadoss C5 gene influences the development of murine myasthenia gravis. , 1988, Journal of immunology.

[35]  D. Alarcón-Segovia,et al.  Role of interleukin 10 in the B lymphocyte hyperactivity and autoantibody production of human systemic lupus erythematosus , 1995, The Journal of experimental medicine.

[36]  V. Oliveira,et al.  IFN-γ production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo , 2005, The Journal of experimental medicine.

[37]  S. Fuchs,et al.  Overexpression of IFN-Induced Protein 10 and Its Receptor CXCR3 in Myasthenia Gravis1 , 2005, The Journal of Immunology.

[38]  J. O’Shea Jaks, STATs, cytokine signal transduction, and immunoregulation: are we there yet? , 1997, Immunity.

[39]  S. Komoly,et al.  Myasthenia gravis: demonstration of membrane attack complex in muscle end-plates. , 1986, Clinical neuropathology.

[40]  P. Christadoss,et al.  The Th2 cytokine IL-4 is not required for the progression of antibody-dependent autoimmune myasthenia gravis. , 1998, Journal of immunology.

[41]  D. Carvajal,et al.  IL-12-Deficient Mice Are Defective in IFNγ Production and Type 1 Cytokine Responses , 1996 .

[42]  J. Link Interferon-gamma, interleukin-4 and transforming growth factor-beta mRNA expression in multiple sclerosis and myasthenia gravis. , 1994, Acta neurologica Scandinavica. Supplementum.

[43]  R. Hirsch,et al.  EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON , 1987, The Lancet.

[44]  S. Nakae,et al.  Suppression of Immune Induction of Collagen-Induced Arthritis in IL-17-Deficient Mice 1 , 2003, The Journal of Immunology.

[45]  Ethan M. Shevach,et al.  CD4+CD25+ suppressor T cells: more questions than answers , 2002, Nature Reviews Immunology.

[46]  G. Bulkley,et al.  Myasthenia Gravis: The Immunobiology of an Autoimmune Disease , 1998 .

[47]  P. Christadoss,et al.  Immunotherapy for myasthenia gravis: a murine model. , 1986, Journal of immunology.

[48]  G. Comi,et al.  IL‐12 is involved in the induction of experimental autoimmune myasthenia gravis, an antibody‐ mediated disease , 1998, European journal of immunology.

[49]  Brigitta Stockinger,et al.  Differentiation and function of Th17 T cells. , 2007, Current opinion in immunology.

[50]  J. Atkinson,et al.  Membrane cofactor protein of complement is present on human fibroblast, epithelial, and endothelial cells. , 1989, The Journal of clinical investigation.

[51]  M. Roncarolo,et al.  Type 1 T regulatory cells , 2001, Immunological reviews.

[52]  J. Banchereau,et al.  Long-term cultured CD40-activated B lymphocytes differentiate into plasma cells in response to IL-10 but not IL-4. , 1995, International immunology.

[53]  M. Milani,et al.  The Susceptibility to Experimental Myasthenia Gravis of STAT6−/− and STAT4−/− BALB/c Mice Suggests a Pathogenic Role of Th1 Cells 1 , 2004, The Journal of Immunology.

[54]  H. P. Benton,et al.  The roles of interleukin-6 and interleukin-10 in B cell hyperactivity in systemic lupus erythematosus , 1999, Inflammation Research.

[55]  J. Banchereau,et al.  Endogenous IL-6 and IL-10 contribute to the differentiation of CD40-activated human B lymphocytes. , 1995, Journal of immunology.

[56]  C. Hsieh,et al.  Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. , 1993, Science.

[57]  R. Caspi,et al.  C57BL/6 mice genetically deficient in IL-12/IL-23 and IFN-γ are susceptible to experimental autoimmune myasthenia gravis, suggesting a pathogenic role of non-Th1 cells. , 2007, The Journal of Immunology.

[58]  C. Chan,et al.  IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. , 1997, Journal of immunology.

[59]  S. Fuchs,et al.  Strain differences in the autoimmune response of mice to acetylcholine receptors , 1976, Nature.

[60]  W. Cowden,et al.  IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. , 1996, Journal of immunology.

[61]  I. Macpherson CANCER IMMUNOCHEMOTHERAPY: THE ROLE OF IMMUNOSTIMULATION , 1974 .

[62]  M. David,et al.  Impaired Development of CD4+ CD25+ Regulatory T Cells in the Absence of STAT1 , 2004, The Journal of experimental medicine.

[63]  J. Wolinsky,et al.  Immune studies in human immunodeficiency virus infection with myasthenia gravis , 1990, Neurology.

[64]  A. Levinson,et al.  In vitro synthesis of antibodies to acetylcholine receptor by peripheral blood cells , 1984, Neurology.

[65]  J. Howard,et al.  T cell recognition of muscle acetylcholine receptor in ocular myasthenia gravis , 2000, Journal of Neuroimmunology.

[66]  H. Weiner,et al.  Orally administered myelin basic protein in neonates primes for immune responses and enhances experimental autoimmune encephalomyelitis in adult animals , 1994, European journal of immunology.

[67]  C. Akdis,et al.  IL‐10‐induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[68]  Mark Ellisman,et al.  Proteolytic nicking of the acetylcholine receptor. , 1980, Biochemistry.

[69]  A. Engel,et al.  Ultrastructural Localization of the Terminal and Lytic Ninth Complement Component (C9) at the Motor End‐plate in Myasthenia Gravis , 1979, Journal of neuropathology and experimental neurology.

[70]  L. Moiola,et al.  Epitopes on the beta subunit of human muscle acetylcholine receptor recognized by CD4+ cells of myasthenia gravis patients and healthy subjects. , 1994, The Journal of clinical investigation.

[71]  K. Matsushima,et al.  T helper 2 cytokines differently regulate monocyte chemoattractant protein-1 production by human peripheral blood monocytes and alveolar macrophages. , 1996, Journal of immunology.

[72]  J. D. de Vries,et al.  Inhibitory and stimulatory effects of IL-10 on human CD8+ T cells. , 1998, Journal of immunology.

[73]  M. Battaglia,et al.  The puzzling world of murine T regulatory cells. , 2002, Microbes and infection.

[74]  M. Shenoy,et al.  Effect of MHC class I and CD8 cell deficiency on experimental autoimmune myasthenia gravis pathogenesis. , 1994, Journal of immunology.

[75]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[76]  R. Pirskanen,et al.  Acetylcholine receptor-reactive T cells in myasthenia gravis: Evidence for the involvement of different subpopulations of T helper cells , 1994, Journal of Neuroimmunology.

[77]  J. Kapp,et al.  Fine-specificity differences in the recognition of an encephalitogenic peptide by T helper 1 and 2 cells , 1993, Journal of Neuroimmunology.

[78]  P. Charukamnoetkanok,et al.  IFN-gamma increases the severity and accelerates the onset of experimental autoimmune uveitis in transgenic rats. , 1999, Journal of immunology.

[79]  P. Berman,et al.  Experimental myasthenia gravis. A murine system , 1980, The Journal of experimental medicine.

[80]  N. Harindranath,et al.  CD40 ligand and appropriate cytokines induce switching to IgG, IgA, and IgE and coordinated germinal center and plasmacytoid phenotypic differentiation in a human monoclonal IgM+IgD+ B cell line. , 1998, Journal of immunology.

[81]  F. Shi,et al.  Role for Interferon-γ in Rat Strains with Different Susceptibility to Experimental Autoimmune Myasthenia Gravis , 2000 .

[82]  J. Howard,et al.  Immunodominant regions for T helper-cell sensitization on the human nicotinic receptor alpha subunit in myasthenia gravis. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[83]  Samir A. Shah,et al.  T Cell–mediated Pathology in Two Models of Experimental Colitis Depends Predominantly on the Interleukin 12/Signal Transducer and Activator of Transcription (Stat)-4 Pathway, but Is Not Conditional on Interferon γ Expression by T Cells , 1998, The Journal of experimental medicine.

[84]  M. Kronenberg,et al.  Going both ways: immune regulation via CD1d-dependent NKT cells. , 2004, The Journal of clinical investigation.

[85]  M. Bellone,et al.  Experimental myasthenia gravis in congenic mice. Sequence mapping and H‐2 restriction of T helper epitopes on the α subunits of Torpedo californica and murine acetylcholine receptors , 1991, European journal of immunology.

[86]  P. Christadoss,et al.  Resistance to Experimental Autoimmune Myasthenia Gravis in IL-6-Deficient Mice Is Associated with Reduced Germinal Center Formation and C3 Production1 , 2002, The Journal of Immunology.

[87]  A. Vincent,et al.  Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis , 1996, Journal of Neuroimmunology.

[88]  R. Caspi,et al.  C57BL/6 Mice Genetically Deficient in IL-12/IL-23 and IFN-γ Are Susceptible to Experimental Autoimmune Myasthenia Gravis, Suggesting a Pathogenic Role of Non-Th1 Cells1 , 2007, Journal of Immunology.

[89]  R. J. Hocking,et al.  TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. , 2006, Immunity.

[90]  R. Hohlfeld,et al.  Induction of HLA-DR expression on human myoblasts with interferon-gamma. , 1990, The American journal of pathology.

[91]  G. Biesecker,et al.  Inhibition of acute passive transfer experimental autoimmune myasthenia gravis with Fab antibody to complement C6. , 1989, Journal of immunology.

[92]  A. Billiau,et al.  Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. , 1994, Journal of immunology.

[93]  A. Levinson,et al.  Suppressor T cells in myasthenia gravis and antibodies to acetylcholine receptor , 1986, Annals of neurology.

[94]  J. Lindstrom,et al.  EXPERIMENTAL AUTOIMMUNE MYASTHENIA GRAVIS: CELLULAR AND HUMORAL IMMUNE RESPONSES * , 1976, Annals of the New York Academy of Sciences.

[95]  A. Zlotnik,et al.  IL-10: a novel cytotoxic T cell differentiation factor. , 1991, Journal of immunology.

[96]  M. Shenoy,et al.  The pathogenic role of acetylcholine receptor α chain epitope within α146-162 in the development of experimental autoimmune myasthenia gravis in C57BL6 mice , 1994 .

[97]  M. Leach,et al.  IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. , 1998, Journal of immunology.

[98]  L. Moiola,et al.  Myasthenia gravis: Residues of the α and γ subunits of muscle acetylcholine receptor involved in formation of immunodominant CD4+ epitopes , 1994 .

[99]  H. Müller-Hermelink,et al.  Thymus in myasthenia gravis. Isolation of T-lymphocyte lines specific for the nicotinic acetylcholine receptor from thymuses of myasthenic patients. , 1988, The Journal of clinical investigation.

[100]  H. Mcdevitt,et al.  In vivo therapy with monoclonal anti-I-A antibody suppresses immune responses to acetylcholine receptor. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[101]  A. Engel,et al.  Immune complexes (IgG and C3) at the motor end-plate in myasthenia gravis: ultrastructural and light microscopic localization and electrophysiologic correlations. , 1977, Mayo Clinic proceedings.

[102]  H. Weiner,et al.  Antigen-driven peripheral immune tolerance: suppression of experimental autoimmmune encephalomyelitis and collagen-induced arthritis by aerosol administration of myelin basic protein or type II collagen. , 1996, Cellular immunology.

[103]  A. Saoudi,et al.  Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune Responses1 , 2005, The Journal of Immunology.

[104]  S. Youssef,et al.  Neutralizing antibodies to IFN-gamma-inducing factor prevent experimental autoimmune encephalomyelitis. , 1998, Journal of immunology.

[105]  A. Billiau,et al.  Defective CD4+CD25+ regulatory T cell functioning in collagen-induced arthritis: an important factor in pathogenesis, counter-regulated by endogenous IFN-γ , 2005, Arthritis research & therapy.

[106]  A. Roberts,et al.  Factors involved in the differentiation of TGF-beta-producing cells from naive CD4+ T cells: IL-4 and IFN-gamma have opposing effects, while TGF-beta positively regulates its own production. , 1998, Journal of immunology.

[107]  P. Christadoss,et al.  Suppression of experimental autoimmune myasthenia gravis in IL-10 gene-disrupted mice is associated with reduced B cells and serum cytotoxicity on mouse cell line expressing AChR , 2000, Journal of Neuroimmunology.

[108]  Zeng-Yu Wang,et al.  T-cell recognition of muscle acetylcholine receptor subunits in generalized and ocular myasthenia gravis , 1998, Neurology.

[109]  J. Howard,et al.  CD4+ T‐epitope repertoire on the human acetylcholine receptor α subunit in severe myasthenia gravis , 1992, Neurology.

[110]  P. Christadoss,et al.  Cooperation of invariant NKT cells and CD4+CD25+ T regulatory cells in the prevention of autoimmune myasthenia , 2006, The Journal of Immunology.

[111]  C. Harris,et al.  Tissue distribution of products of the mouse decay‐accelerating factor (DAF) genes. Exploitation of a Daf1 knock‐out mouse and site‐specific monoclonal antibodies , 2001, Immunology.

[112]  L. Harrison,et al.  Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice. , 1991, The Journal of clinical investigation.

[113]  H. Kaminski,et al.  Markedly enhanced susceptibility to experimental autoimmune myasthenia gravis in the absence of decay-accelerating factor protection. , 2002, The Journal of clinical investigation.

[114]  S. Romagnani,et al.  The Th1/Th2 paradigm. , 1997, Immunology today.

[115]  S. Dunn,et al.  Functional stability of Torpedo acetylcholine receptor. Effects of protease treatment. , 1982, Biochemistry.

[116]  P. Christadoss,et al.  Role of IL-5 during primary and secondary immune response to acetylcholine receptor , 2002, Journal of Neuroimmunology.

[117]  Zeng-Yu Wang,et al.  Thl epitope repertoire on the a subunit of human muscle acetylcholine receptor in myasthenia gravis , 1997, Neurology.

[118]  J. Howard,et al.  T helper cell recognition of muscle acetylcholine receptor in myasthenia gravis. Epitopes on the gamma and delta subunits. , 1993, The Journal of clinical investigation.

[119]  Zeng-Yu Wang,et al.  T Cell Recognition of the Acetylcholine Receptor in Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.

[120]  R. Ulevitch,et al.  Role of complement in the pathogenesis of experimental autoimmune myasthenia gravis , 1978, The Journal of experimental medicine.

[121]  J. Banchereau,et al.  Human interleukin 10 induces naive surface immunoglobulin D+ (sIgD+) B cells to secrete IgG1 and IgG3 , 1994, The Journal of experimental medicine.

[122]  N. Sarvetnick,et al.  Loss of pancreatic islet tolerance induced by beta-cell expression of interferon-gamma. , 1990, Nature.

[123]  P. Karachunski,et al.  Prevention of experimental myasthenia gravis by nasal administration of synthetic acetylcholine receptor T epitope sequences. , 1997, The Journal of clinical investigation.

[124]  P. Christadoss,et al.  Mapping myasthenia gravis-associated T cell epitopes on human acetylcholine receptors in HLA transgenic mice. , 2002, The Journal of clinical investigation.

[125]  P. Limburg,et al.  Anti-acetylcholine receptor antibodies in myasthenia gravis Part 1. Relation to clinical parameters in 250 patients , 1983, Journal of the Neurological Sciences.

[126]  P. Karachunski,et al.  Nasal Administration of Synthetic Acetylcholine Receptor T Epitopes Affects the Immune Response to the Acetylcholine Receptor and Prevents Experimental Myasthenia Gravis a , 1998, Annals of the New York Academy of Sciences.

[127]  S. Nakae,et al.  IL-17 Plays an Important Role in the Development of Experimental Autoimmune Encephalomyelitis1 , 2006, The Journal of Immunology.

[128]  S. Akira,et al.  STAT family of transcription factors in cytokine-mediated biological responses. , 2000, Cytokine & growth factor reviews.

[129]  A. Vincent,et al.  Anti-acetylcholine receptor antibodies. , 1980, Journal of neurology, neurosurgery, and psychiatry.

[130]  Xiaojian Huang,et al.  Genetic Absence of γ-Interferon Delays but Does Not Prevent Diabetes in NOD Mice , 1996, Diabetes.

[131]  Th1/Th2 cells. , 1999, Inflammatory bowel diseases.

[132]  R. Hohlfeld,et al.  Autoimmune human T lymphocytes specific for acetylcholine receptor , 1984, Nature.

[133]  M. Toda,et al.  Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. , 1995, Journal of immunology.

[134]  Kenneth M. Murphy,et al.  Functional diversity of helper T lymphocytes , 1996, Nature.

[135]  M. Raftery,et al.  The nicotinic acetylcholine receptor: structure and autoimmune pathology. , 1994, Critical reviews in biochemistry and molecular biology.

[136]  M. Kronenberg,et al.  Transgenic Expression of IL-10 in T Cells Facilitates Development of Experimental Myasthenia Gravis1 , 2001, The Journal of Immunology.

[137]  L. Rassenti,et al.  HLA-DQ BETA-CHAIN POLYMORPHISM LINKED TO MYASTHENIA GRAVIS , 1986, The Lancet.

[138]  H. Weiner,et al.  Induction and mechanism of action of transforming growth factor‐β‐secreting Th3 regulatory cells , 2001, Immunological reviews.

[139]  J. Lafaille The role of helper T cell subsets in autoimmune diseases. , 1998, Cytokine & growth factor reviews.

[140]  Zeng-Yu Wang,et al.  Myasthenia in SCID mice grafted with myasthenic patient lymphocytes , 1999, Neurology.

[141]  J. Dichgans,et al.  Ocular myasthenia gravis , 1993, Documenta Ophthalmologica.

[142]  S. Constant,et al.  Induction of Th1 and Th2 CD4+ T cell responses: the alternative approaches. , 1997, Annual review of immunology.

[143]  L. Chen,et al.  In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. , 1995, Journal of immunology.

[144]  R. Hirsch,et al.  Treatment of multiple sclerosis with gamma interferon , 1987, Neurology.

[145]  P. Christadoss,et al.  GENETIC CONTROL OF AUTOIMMUNITY TO ACETYLCHOLINE RECEPTORS: ROLE OF Ia MOLECULES * , 1981, Annals of the New York Academy of Sciences.

[146]  J. Bromberg,et al.  IL-10 immunosuppression in transplantation. , 1995, Current opinion in immunology.

[147]  G. Trinchieri,et al.  B7 and interleukin 12 cooperate for proliferation and interferon gamma production by mouse T helper clones that are unresponsive to B7 costimulation , 1994, The Journal of experimental medicine.

[148]  L. Steinman,et al.  Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). , 1996, Journal of immunology.

[149]  S. Fuchs,et al.  Suppression of ongoing experimental myasthenia by oral treatment with an acetylcholine receptor recombinant fragment. , 1999, The Journal of clinical investigation.

[150]  A. Saoudi,et al.  Functional defect of regulatory CD4(+)CD25+ T cells in the thymus of patients with autoimmune myasthenia gravis. , 2005, Blood.

[151]  P. Karachunski,et al.  Interleukin-4 deficiency facilitates development of experimental myasthenia gravis and precludes its prevention by nasal administration of CD4+ epitope sequences of the acetylcholine receptor , 1999, Journal of Neuroimmunology.

[152]  T. Olsson,et al.  Depletion of CD8+ T cells suppresses the development of experimental autoimmune myasthenia gravis in Lewis rats , 1995, European journal of immunology.

[153]  R. Longhi,et al.  Oral administration of an immunodominant T-cell epitope downregulates Th1/Th2 cytokines and prevents experimental myasthenia gravis. , 1999, The Journal of clinical investigation.

[154]  Shizuo Akira,et al.  Functional Roles of STAT Family Proteins: Lessons from Knockout Mice , 1999, Stem cells.

[155]  A. Lindén,et al.  Interleukin-17 family members and inflammation. , 2004, Immunity.

[156]  M. Veldhoen,et al.  TGFbeta1, a "Jack of all trades": the link with pro-inflammatory IL-17-producing T cells. , 2006, Trends in immunology.

[157]  P. Bedossa,et al.  Prevention of diabetes in NOD mice treated with antibody to murine IFN gamma. , 1991, Journal of autoimmunity.

[158]  F. Clementi,et al.  Cellular immune response to acetylcholine receptor in myasthenia gravis , 1979, Neurology.

[159]  J. Lindstrom,et al.  Adoptive protection from experimental myasthenia gravis with T cells from mice treated nasally with acetylcholine receptor epitopes , 2002, Journal of Neuroimmunology.

[160]  M. Seldin,et al.  Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. Duplicated genes encode glycosylphosphatidylinositol-anchored and transmembrane forms. , 1995, Journal of immunology.

[161]  J. Howard,et al.  Human thymuses express incomplete sets of muscle acetylcholine receptor subunit transcripts that seldom include the δ subunit , 2001, Muscle & nerve.

[162]  N. Dybdal,et al.  Genetic absence of gamma-interferon delays but does not prevent diabetes in NOD mice. , 1996, Diabetes.

[163]  T. Olsson,et al.  Both CD4+ and CD8+ T cells are essential to induce experimental autoimmune myasthenia gravis , 1996, The Journal of experimental medicine.

[164]  M. Milani,et al.  Absence of IL-4 Facilitates the Development of Chronic Autoimmune Myasthenia Gravis in C57BL/6 Mice1 , 2003, The Journal of Immunology.

[165]  M. Davisson,et al.  The mouse mutation severe combined immune deficiency (scid) is on chromosome 16 , 2006, Immunogenetics.

[166]  Link,et al.  Increased levels of circulating acetylcholine receptor (AChR)‐reactive IL‐10‐secreting cells are characteristic for myasthenia gravis (MG) , 1999, Clinical and experimental immunology.

[167]  L. Moiola,et al.  Immunoregulatory CD8+ cells recognize antigen-activated CD4+ cells in myasthenia gravis patients and in healthy controls. , 1995, Journal of immunology.

[168]  L. Moiola,et al.  Myasthenia gravis. T epitopes on the delta subunit of human muscle acetylcholine receptor. , 1991, Journal of immunology.

[169]  S. Meri,et al.  Distribution of protectin (CD59), a complement membrane attack inhibitor, in normal human tissues. , 1991, Laboratory investigation; a journal of technical methods and pathology.

[170]  M. Bosma,et al.  Defective V‐to‐J recombination of T cell receptor γ chain genes in scid mice , 1990, European journal of immunology.

[171]  S. Fuchs,et al.  Role of Tolerogen Conformation in Induction of Oral Tolerance in Experimental Autoimmune Myasthenia Gravis1 , 2000, The Journal of Immunology.